Article
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
American journal of hematology - 1 May 2013
Al-Kali Aref, Quintás-Cardama Alfonso, Luthra Raja, Bueso-Ramos Carlos, Pierce Sherry, Kadia Tapan, Borthakur Gautam, Estrov Zeev, Jabbour Elias, Faderl Stefan, Ravandi Farhad, Cortes Jorges, Tefferi Ayalew, Kantarjian Hagop, Garcia-Manero Guillermo
Abstract excerpt
RAS is an oncogene frequently mutated in human cancer. RAS mutations have been reported in 10-15% of cases of acute myeloid leukemia (AML) but they appear to be less frequent among patients with myelodysplastic syndrome (MDS). The impact of RAS mutations in patients with MDS is unclear. We conducted a retrospective study in 1,067 patients with newly diagnosed MDS for whom RAS mutational analysis was available....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.